日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors

一项评估沃罗拉尼在晚期实体瘤患者中安全性、耐受性和药代动力学的I期、首次人体剂量递增研究

Bendell, Johanna C; Patel, Manish R; Moore, Kathleen N; Chua, Cynthia C; Arkenau, Hendrik-Tobias; Dukart, Gary; Harrow, Kim; Liang, Chris

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

恩沙替尼(X-396)治疗ALK阳性非小细胞肺癌:一项首次人体I/II期多中心研究的结果

Horn, Leora; Infante, Jeffrey R; Reckamp, Karen L; Blumenschein, George R; Leal, Ticiana A; Waqar, Saiama N; Gitlitz, Barbara J; Sanborn, Rachel E; Whisenant, Jennifer G; Du, Liping; Neal, Joel W; Gockerman, Jon P; Dukart, Gary; Harrow, Kimberly; Liang, Chris; Gibbons, James J; Holzhausen, Allison; Lovly, Christine M; Wakelee, Heather A

Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel.

使用 FLT PET/CT 对采用 X-82 和多西他赛序贯联合治疗的晚期实体恶性肿瘤进行药效学研究

Scarpelli Matthew, Rampurwala Murtuza, Eickhoff Jens, Carmichael Lakeesha, Heideman Jennifer, Binger Kimberly, Kolesar Jill, Perlman Scott, Harrow Kim, Dukart Gary, Liang Chris, Jeraj Robert, Liu Glenn, Bruce Justine Yang

Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia

替加环素在社区获得性肺炎患者中的药代动力学-药效学研究

Rubino, Christopher M; Bhavnani, Sujata M; Forrest, Alan; Dukart, Gary; Dartois, Nathalie; Cooper, Angel; Korth-Bradley, Joan; Ambrose, Paul G